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Peroxisome proliferator-activated receptor-γ (PPARγ) is the members of the nuclear receptor superfamily as a master
transcriptional factor that promotes diﬀerentiation of preadipocytes by activating adipose-speciﬁc gene expression. Although
PPARγ isexpressedpredominantlyinadiposetissueandassociatedwithadipocytediﬀerentiationandglucosehomeostasis,PPARγ
is also present in a variety of cell types including vascular cells and cardiomyocytes. Activation of PPARγ suppresses production
of inﬂammatory cytokines, and there is accumulating data that PPARγ ligands exert antihypertrophy of cardiomyocytes and
anti-inﬂammatory, antioxidative, and antiproliferative eﬀects on vascular wall cells and cardiomyocytes. In addition, activation
of PPARγ is implicated in the regulation of endothelial function, proliferation and migration of vascular smooth muscle cells,
and activation of macrophages. Many studies suggest that PPARγ ligands not only ameliorate insulin sensitivity, but also have
pleiotropic eﬀects on the pathophysiology of atherosclerosis, cardiac hypertrophy, ischemic heart, and myocarditis.
1.Introduction
Cardiovascular disease (CVD) is the leading cause of mor-
bidity and mortality in the western world. Major risk factors
for CVD is hypertension, dyslipidemia, and hyperglycemia
includinginsulinresistance[1].Manyantihypertensivedrugs
arewidelyusedtonormalize bloodpressure,anditsevidence
of CVD preventive eﬀect has been clariﬁed [2]. Moreover,
several classes of drugs for dyslipidemia, including bile acid
sequestrants, ﬁbrates, and statins, have been used historically
to reduce cholesterol levels and reduced the morbidity and
mortality of CVD [3]. Meanwhile, insulin has been used
to improve hyperglycemia as a pivotal controller of basic
glucose metabolism. Since the insulin self-injection of every
day is intolerable [4], other agents that are used to help
control elevated glucose concentrations in diabetes have
been developed. These agents can decrease glucose produc-
tion by the liver (metformin), stimulate insulin secretion
(sulfonylureas and meglitinides), retard glucose absorption
from the gastrointestinal tract (-glycosidase inhibitors),
slow intestinal motility (amylin), reduce insulin resistance
(thiazolidinediones (TZDs)), or replace gastrointestinal pep-
tides known to be active in glucose metabolism (GLP-1
analogs or dipeptidyl peptase IV inhibitors). TZDs are a
class of glucose-lowering oral medications which improve
glycemic control and improve insulin sensitivity in muscle
and liver [5]. TZDs exert their hypoglycemic properties
by reducing insulin resistance through stimulation of a
nuclear receptor, peroxisome proliferator-activated receptor
γ (PPARγ). PPARγ is associated with adipocyte diﬀerentia-
tionandglucosehomeostasis.PPARγ isexpressedinavariety
of cell types, including adipocytes, macrophages, vascular
smooth muscle cells (VSMCs), endothelial cells (ECs), and
cardiomyocytes [6–11]. Since it was reported that activation
of PPARγ suppresses production of inﬂammatory cytokines
inactivatedmacrophages,manyresearcherspaidattentionto
PPARγ as a new therapeutic target for CVD.
RXR, which interacts with the PPARγ,i sa c t i v a t e d
by 9-cis retinoic acid. When combined as a PPARγ:RXR
heterodimer, the PPARγ ligands and 9-cis retinoic acid
act synergistically on PPARγ responses. The corepressor
complex constitutes corepressor proteins, such as nuclear2 PPAR Research
receptor corepressor (NCoR) and silencing mediator of
retinoid and thyroid hormone receptors, histone deacety-
lases (HDACs) and transducin β-like protein 1 (TBL1).
HDACs are essential in maintaining repressed chromatin
structure and TBL1 exchanges a corepressor complex for a
coactivator complex in the presence of ligand [12]. Many
n u c l e a rr e c e p t o r sa r ep r o p o s e dt os e q u e s t e ri n ﬂ a m m a t o r y
transcription factors, such as nuclear factor-κB( N F - κB) and
AP-1, by inhibiting their DNA-binding activities, resulting
in inhibition of inﬂammatory target genes. In the presence
of ligand, PPARγ also interacts with inﬂammatory tran-
scription factors and inhibits their DNA-binding activities.
PPARγ blocks clearance of the corepressor complex in a
ligand-dependent manner, and PPARγ stabilizes the core-
pressor complex bound to the promoter of inﬂammatory
genes [13]. It was demonstrated that PPARγ associates with
the protein inhibitor of activated STAT1 (PIAS1), which
is a small ubiquitin-like modiﬁer (SUMO)-E3 ligase, in a
ligand-dependent manner. PIAS1-induced SUMOylation of
the ligand-binding domain of PPARγ enables the receptor
to maintain NCoR on the promoter of inﬂammatory genes
[14]. These are the suggested mechanisms of PPARγ transre-
pression.
Activity of PPARγ is depressed by phosphorylation of a
serine residue (Ser112) in the N-terminal domain, mediated
by a member of the mitogen-activated protein (MAP) kinase
family, extracellular signal-regulated protein kinase (ERK).
In addition, another member of MAP kinase family, c-
Jun N-terminal kinase (JNK), also phosphorylates PPARγ
at Ser82 and reduces the transcriptional activity of PPARγ.
The association of PPARγ polymorphism with metabolic
syndrome has also been examined [15, 16]. In the presence
of ligand, PPARγ bind to coactivator complexes, resulting in
theactivationoftargetgenes.Intheabsenceofligand,PPARγ
binds to the promoters of several target genes and associates
with a corepressor complex, leading to active repression of
target genes. This process is referred to as active repression.
Several ligands, which bind to PPARγ, resulting in
conformational change and activation of PPARγ,h a v eb e e n
discovered [17]. 15d-PGJ2, which is the PGD2 metabolite,
was the ﬁrst endogenous ligand for PPARγ to be discovered.
Although 15d-PGJ2 is the most potent natural ligand of
PPARγ, the extent to which its eﬀects are mediated through
PPARγ in vivo remains to be determined. Two compo-
nents of oxidized low density lipoprotein (ox-LDL), the
9-hydroxy and 13-hydroxy octadecadienoic acids (HODE),
are also potent endogenous activators of PPARγ [18, 19].
Activation of 12/15-lipoxygenase induced by interleukin
(IL)-4 also produced endogenous ligands for PPARγ [20],
however, whether these natural ligands act as physiological
PPARγ ligands in vivo remains unknown. TZDs, such as
troglitazone, pioglitazone, ciglitazone, and rosiglitazone are
pharmacological ligands of PPARγ. They bind to PPARγ
with various aﬃnities and exerts insulin-sensitizing and
hypoglycemic eﬀects by activating PPARγ.H o w e v e r ,t h e
molecular mechanisms by which TZDs aﬀect insulin resis-
tance and glucose homeostasis are not fully understood.
Theyseemtomediatetheireﬀectsprimarily throughadipose
tissue, because TZDs alter the expression level of genes
that are involved in lipid uptake, lipid metabolism and
insulinactioninadipocytes.TZDsenhanceadipocyteinsulin
signaling and reduce the release of free fatty acids. TZDs also
decrease the inﬂammation of adipose tissue that is induced
by obesity and contributes to increased insulin resistance.
TZDs improve insulin sensitivity in skeletal muscle and liver,
which is the main insulin-sensitive organs, through these
multiple adipocentric actions. TZDs has been demonstrated
to have an anti-inﬂammatory eﬀect, leading to initiation
of treatment trials for patients with inﬂammatory diseases
including CVD [21].
2. Role of PPARγ in Atherosclerosis
Atherosclerosis is a chronic, complex and progressive path-
ological process in large- and medium-sized arteries.
Atherosclerotic vascular disease is the most common cause
of vascular complications, including stroke, myocardial
infarction (MI), and aortic aneurysms/dissections. There are
multiple potential mechanisms contributing to susceptibility
toatherosclerosis.Injuryoftheendothelium,proliferationof
VSMCs, migration of monocytes/macrophages, and the reg-
ulatory network of growth factors and cytokines are impor-
tant in the development of atherosclerosis. Hypertension,
dyslipidemia, increased free radicals from smoking and dia-
betes causes chronic inﬂammation of the vascular wall and
abnormal immune response. Their formation is triggered
by endothelial cell activation and dysfunction causing the
release of vasoactive molecules and cytokines, which stimu-
late an inﬂammatory response and recruitment/migration of
leukocytes into the arterial wall [22]. Increased expression of
adhesion molecules such as vascular cell adhesion molecule-
1 (VCAM-1), intracellular adhesion molecule-1 (ICAM-1),
E-selectin and P-selectin within the atherosclerotic lesion
stimulates monocyte recruitment and transmigration into
the arterial intima [23], and accumulation of lipids and
extracellular matrix may further amplify the local inﬂam-
matory response [24]. Monocytes rapidly mature into tissue
macrophages which take up oxidized lipoproteins via scav-
engerreceptorswithinthesubendothelialspace.Intracellular
accumulation of cholesterol results in the characteristic
formation of foam cells and stimulates macrophages to
secrete cytokines, growth factors, and other mediators that
promote smooth muscle cell proliferation and potentiate
the inﬂammatory response, leading to arterial remodeling.
A vicious circle of inﬂammation and cell inﬁltration causes
plaque progression, which interfere with the normal blood
ﬂow. Eventually, the plaque ruptures due to degradation
by macrophage-induced matrix metalloproteinases (MMPs)
and hydrolytic enzymes, resulting in thrombus formation
and tissue infarction [22].
PPARγ has anti-inﬂammatory eﬀect and PPARγ ligands
have been shown to reduce production of inﬂammatory
cytokines,suchasIL-1β,IL-6,induciblenitricoxidesynthase
and tumor necrosis factor-α (TNF-α), by inhibiting the
activity of transcription factors such as activator protein-
1 (AP-1), signal transducers and activators of transcription
(STAT), and NF-κB in monocytes/macrophages [6, 7]. ThesePPAR Research 3
ﬁndings suggest that PPARγ activation may have beneﬁcial
eﬀects in modulating inﬂammatory responses in atheroscle-
rosis [25, 26]. Interestingly, expression of PPARγ has been
demonstrated in atherosclerotic plaques [25]. Macrophages
aﬀect the vulnerability of plaque to rupture, and they are
implicated in the secretion of matrix metalloproteinases
(MMPs), enzymes that are important in the degradation of
extracellular matrix. In macrophages and VSMCs, PPARγ
ligands have been shown to reduce the expression of MMP-
9, resulting in the inhibition of migration of VSMCs,
and plaque destabilization [7, 8]. Although activation of
T lymphocytes represents a critical step in atherosclerosis,
PPARγ ligands also reduce the activation of T lymphocytes
[27]. T lymphocytes also express PPAR-γ, cells important in
atherosclerosis, and can limit their chemokine elaboration
[28]. Classically activated macrophages (M1) express a high
level of proinﬂammatory cytokines and reactive oxygen
species, whereas alternatively activated macrophages (M2)
play an anti-inﬂammatory role in atherosclerosis. Recently,
i tw a sr e p o r t e dt h a tP P A R γ is a key regulator of M1/M2
polarization [29]. PPARγ agonists prime monocytes into M2
and PPARγ expression is enhanced by M2 diﬀerentiation
[30]. VSMC proliferation and migration are also critical
events in atherosclerosis and vascular-intervention-induced
restenosis. TZDs inhibit both these changes in the VSMCs
and neointimal thickening after vascular injury [31–34].
Furthermore, TZDs induce apoptosis of VSMCs via p53 and
Gadd45 [35, 36]. Angiotensin II (AngII) plays an important
role in vascular remodeling via the AngII type 1 receptor
(AT1R) and accelerates atherosclerosis. Although AngII
induces transcriptional suppression of PPARγ,a c t i v a t i o no f
PPARγ inhibits AT1R gene expression at a transcriptional
level in VSMCs [37–39]. Expression of adhesion molecule
by ECs, leading to adhesion of leukocytes, is a critical
early step in atherosclerosis. PPARγ ligands inhibit the
expression of vascular cell adhesion molecule-1 (VCAM-
1) and intercellular adhesion molecule-1 and decreased
production of chemokines, such as IL-8 and monocyte
chemotacticprotein-1(MCP-1)viasuppressionsofAP-1and
NF-κB activities in ECs [40–42]. PPARγ ligands also inhibit
MCP-1-induced monocytes migration [43]. Endothelin-1
(ET-1) is involved in the regulation of vascular tone and
endothelial functions, and induces proliferation of VSMCs.
In bovine aortic ECs, PPARγ ligands suppressed transcrip-
tion of the ET-1 promoter by interfering with AP-1 [44].
PPARγ activation by major oxidized lipid components of ox-
LDL, 9-HODE and 13-HODE has an important role in the
development of lipid-accumulating macrophages through
transcriptional induction of CD36, a scavenger receptor.
[45]. These ﬁndings suggest that atherogenic ox-LDL par-
ticles could induce their own uptake through activation of
PPARγ and expression of CD36, leading to atherosclerosis.
However, several studies have demonstrated that activation
of PPARγ does not promote lipid accumulation in either
mouse or human macrophages [46–48]. Liver X receptor α
(LXRα) is an oxysterol receptor that promotes cholesterol
excretion and eﬄux by modulating expression of ATP-
binding cassette transporter 1 (ABCA1) [47, 48]. LXRα
was recently identiﬁed as a direct target of PPARγ in
mouse and human macrophages [49, 50]. Although the
PPARγ-induced increase in CD36 expression might accel-
erate lipid uptake in macrophages, subsequent activation
of LXRα and upregulation of ABCA1 appear to induce
lipid eﬄux. Diep et al. have demonstrated that rosiglitazone
and pioglitazone attenuate the development of hyperten-
sion and structural abnormalities, and improve endothelial
dysfunction in AngII-infused rats [51]. These TZDs also
prevented upregulation of AT1R, cell cycle proteins, and
inﬂammatory mediators. Rosiglitazone, but not the PPARα
ligand fenoﬁbrate, prevented hypertension and endothelial
dysfunction in DOCA-salt hypertensive rats [52]. It has been
reported that serum levels of the soluble CD40 ligand are
elevated in acute coronary syndrome and associated with
increased cardiovascular risk. Treatment with rosiglitazone
decreased the serum levels of soluble CD40 and MMP-9 in
type 2 diabetic patients with coronary artery disease [53].
Taking all the evidence together, PPARγ ligands may prevent
the progression of atherosclerotic lesions, particularly in
patients with DM (Figure 1).
3. Role of PPARγ inIschemic Heart Disease
Ischemic heart disease (IHD) is a disease characterized by
ischemia to the heart muscle, usually due to coronary artery
disease (atherosclerosis of the coronary arteries). Prolonged
ischemia leads to cardiomyocyte death which is followed
by a series of structural and functional alterations in the
viable myocardium, known as cardiac remodeling. Adaptive
changes in the extracellular matrix and in cardiomyocyte
biology occur, which are initially able to maintain con-
tractile function. However, progressive cardiac remodeling
leads to chamber dilatation, contractile dysfunction and
ultimately heart failure [54, 55]. Inﬁltration of neutrophils
and macrophages is known to enhance the inﬂammatory
response to myocardial ischemia and in combination with
rapid accumulation of ROS within the ischemic zone can
lead to tissue necrosis upon reperfusion [56]. This is further
ampliﬁed by activation of redox-sensitive transcription fac-
tors, such as NF-κB and AP-1, which control the expression
of proinﬂammatory mediators, such as IL-12 and TNFα.
Indeed, in an experimental rat model, inhibition of NF-κB
has been demonstrated to reduce reperfusion injury after a
brief period of ischemia [57]. Furthermore, upregulation of
AP-1 has been observed in cardiomyocytes in the presence of
increased levels of ROS [58], such as those observed during
ischemia and reperfusion, suggesting that this transcription
factor may be involved in the pathogenesis of ischemia and
subsequent reperfusion.
As the eﬀects of PPARγ on the heart are not fully
understood, we and others have examined whether PPARγ is
involvedinvariousheartdiseases.Althoughtheexpressionof
PPARγ incardiacmyocytesislowcomparedwithadipocytes,
PPARγ ligands seem to act on cardiac myocytes [11, 59].
We demonstrated that PPARγ ligands inhibited the cardiac
expression of TNF-α at the transcriptional level, in part
by antagonizing NF-κB and AP-1 activity [11, 60]. Because
TNF-α expression is elevated in the failing heart and has4 PPAR Research
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Figure 1: Action of PPARγ on atherosclerotic lesion. PPARγ act on endothelial cell, smooth muscle cell, and macrophage.
a negative inotropic eﬀect on cardiac myocytes, treatment
with PPARγ ligands may prevent the development of CHF.
Diabetic cardiomyopathy, which is characterized by systolic
and diastolic dysfunction, is a major complication DM,
and therefore TZDs seem to be beneﬁcial for the impaired
cardiac function in patients with DM. Following our study,
the role of PPARγ in myocardial ischemia-reperfusion (IR)
injury has been elucidated [61–64]. In animal models,
PPARγ ligands reduced the size of the myocardial infarct and
improvedcontractiledysfunctionafterIRthroughinhibition
of the inﬂammatory response. IR injury activates JNK, and
subsequently JNK induces increases in both AP-1 DNA-
binding activity and apoptotic cells. It has been shown in
ratsthatrosiglitazoneinhibitstheactivationofJNKandAP-1
aftermyocardialIR[62].Furthermore,pioglitazone hasbeen
reported to attenuate left ventricular remodeling and heart
failure after myocardial infarction (MI) in mice [65]. Both of
these eﬀects of TZDs ligands were associated with decreases
in inﬂammatory cytokines and chemokines [65, 66].
4. Role of PPARγ in CardiacHypertrophy
Cardiachypertrophyischaracterizedbymaladaptivechanges
in myocardial structure and function, which are collectively
known as cardiac remodeling. Cardiac hypertrophy is an
independent risk factor for heart failure, arrhythmia, and
sudden death and is one of the most potent predictors of
adverse cardiovascular outcomes in hypertensive patients
[67, 68]. Initially, the heart compensates for the increased
wall stress by undergoing signiﬁcant alterations in cardiomy-
ocyte biology and in the extracellular matrix. However,
progressive LV hypertrophy combined with loss of collagen
crosslinking and myocyte slippage causes increased wall
stress leading to cardiac chamber dilatation, contractile
dysfunction, and ultimately decompensated congestive heart
failure (CHF) [69]. Changes in structure and function of
the heart are mediated by a variety of mechanical, neu-
ronal and hormonal factors. Several antihypertensive drugs
such as angiotensin-converting enzyme (ACE) inhibitors,
angiotensin receptor blocker (ARB), and β-blockers are
known to attenuate cardiac remodeling and have morbid-
ity/mortality beneﬁts [70, 71], but its eﬀect is not enough.
The PPARγ ligands, troglitazone, pioglitazone, and
rosiglitazone, inhibited AngII-induced hypertrophy of neo-
natal rat cardiac myocytes [72–74]. Because generalized
PPARγ gene deletion causes embryonic lethality, we exam-
ined the role of PPARγ in the development of cardiac
hypertrophy in vivo using heterozygous PPARγ-deﬁcient
(PPARγ+/−)m i c e[ 72]. Pressure overload-induced cardiac
hypertrophywasmoreprominentinheterozygousPPARγ+/−
mice than in wild-type (WT) mice. Treatment with pioglita-
zone strongly inhibited the pressure overload-induced car-
diac hypertrophy in WT mice and moderately in PPARγ+/−
mice [72]. Thereafter, 2 other groups examined the role of
PPARγ in the heart by using cardiomyocyte-speciﬁc PPARγ
knockout mice [75, 76]. Duan et al. reported that these
mice develop cardiac hypertrophy through elevated NF-κB
activity [75], and unexpectedly, rosiglitazone-induced car-
diac hypertrophy in both the WT mice and cardiomyocyte-
speciﬁc PPARγ knockout mice through activation of p38
MAP kinase independent of PPARγ. Ding et al. reported
that cardiomyocyte-speciﬁc PPARγ knockout mice displayed
cardiac hypertrophy from approximately 3 months of age
and then progress to dilated cardiomyopathy (DCM), and
most mice died from heart failure within 1 year after
birth [76]. Mitochondrial oxidative damage and reduced
expression of manganese superoxide dismutase were rec-
ognized in the cardiomyocyte-speciﬁc PPARγ knockout
mice [76]. These mice models demonstrate that PPARγ
is essential for protecting cardiomyocytes from stress and
oxidative damage, although the expression level of PPARγ
in cardiomyocytes is low. On the other hand, Son et al.
demonstrated that cardiomyocyte-speciﬁc PPARγ transgenic
mice develop DCM associated with increased uptake of both
fatty acid and glucose [77]. Rosiglitazone increased this
glucolipotoxicity in cardiomyocyte-speciﬁc PPARγ trans-
genic mice. If PPARγ in the heart is expressed at a high
level, rosiglitazone may cause cardiotoxic eﬀects; however,
as noted earlier the expression level of PPARγ in the
heart is quite low. Because cardiac hypertrophy can be
seen even in normotensive diabetic patients, and diabetic
cardiomyopathy is a major complication of DM, antidiabetic
agents such as the TZDs would be expected to have beneﬁcial
eﬀects on cardiac hypertrophy and dysfunction in patients
with DM.PPAR Research 5
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Figure 2:Histopathologyoftheheartsectionofexperimentalmyocarditis[78].(N);controlheart,(E);heartfromexperimentalmyocarditis
treated with saline, (P); heart from experimental myocarditis treated with pioglitazone. The upper panel shows hematoxylin-eosin staining
(scale bars indicate 200μm), the middle panel shows van Gieson staining (scale bars indicate 400μm), and the lower panel shows
immunostaining of inﬁltration of inﬂammatory macrophages (scale bars indicate 200μm) in the heart of experimental myocarditis rats.
The degree of inﬂammation, ﬁbrosis and inﬁltration of inﬂammatory macrophages was signiﬁcantly improved by the treatment with
pioglitazone.
5. Role of PPARγ inMyocarditis
Myocarditis is a potentially life-threatening disease that pri-
marilyaﬀectschildrenandyoungadultswithsometimesdev-
astating consequences, including sudden death. The primary
long-term consequences are DCM and CHF. Myocarditis
presents with a spectrum of symptoms ranging from mild
dyspnea or chest pain that spontaneously resolves without
treatmenttocardiogenicshock andsuddendeath.Themajor
long-term consequence is DCM with CHF. Common viral
infections are the most frequent cause of myocarditis, but
otherpathogens,hypersensitivityreactions,andsystemicand
autoimmune diseases have also been implicated.
Rat experimental autoimmune myocarditis (EAM)
model is a T cell-mediated disease characterized by inﬁl-
tration of T cells and macrophages, leading to massive
myocarditis necrosis, which develops into heart failure in
the chronic phase [79]. Two weeks after immunization with
porcine cardiac myosin, small numbers of CD4+ T cells and
macrophages start to inﬁltrate into the myocardium and
various cytokines are expressed. Macrophage inﬂammatory
protein-1α (MIP-1α) is a C-C chemokine that induces
leukocyte accumulation in tissue sites of inﬂammation. We
previously demonstrated that MIP-1α mRNA and protein
are highly expressed in the hearts of rats with EAM from
day 11 after ﬁrst immunization (Figure 2)[ 79]. MIP-1α
drives naive helper T (Th) cells to diﬀerentiate into type
1 helper T (Th1) cells in the early stage, and thereafter
several cytokines are secreted by Th1 cells or macrophages.
Th1 cells produce interferon-γ (IFN-γ), which is mainly
involved in cell-mediated immune responses, whereas type
2 helper T (Th2) cells produce IL-4, IL-5, IL-6, IL-10, and
IL-13, which participate in humoral responses. Immune
dysfunction associated with autoimmune disease is known
to involve an imbalance between Th1 and Th2 cells. We and
others have reported that pioglitazone treatment markedly6 PPAR Research
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Figure 3: Inhibitory mechanisms of PPARγ on autoimmune
induced myocarditis. PPARγ inhibits the progression of autoim-
mune induced myocarditis via inhibition of the activation of
Th1/Th2 balance, MIP-1α, proinﬂammatory cytokines TNF-α/IL-
1β, and macrophage.
reduces the severity of myocarditis in a rat model of EAM
[78,80].Pioglitazonesuppressedexpressionofinﬂammatory
cytokines and activation of myocardiogenic T cells in the
myocardium of EAM rats [80]. The mRNA levels of MIP-
1α were upregulated in the hearts of EAM rats, but not in
the hearts of those in the pioglitazone group. The expression
of inﬂammatory cytokines such as IL-1β and TNF-α was
upregulated in EAM rats and it was reduced by the treatment
with pioglitazone. Furthermore, treatment with pioglitazone
decreased the Th1 cytokine (IFN-γ) genes and increased the
expression levels of Th2 cytokine (IL-4) gene [78]. These
results suggest that PPARγ ligands change the orientation of
immune responses by favoring Th2 response. The treatment
with PPARγ ligands may have beneﬁcial eﬀects on myocardi-
tis by inhibiting MIP-1α expression and modulating the
Th1/Th2 balance (Figure 3). Further studies are necessary to
elucidate whether PPARγ ligands have beneﬁcial eﬀects on
human myocarditis.
6. ClinicalEfﬁcacyandSafetyofTZDTreatment
TZDs (or glitazones) are widely used in the treatmentof type
II diabetes, respectively. Although these are their primary
indications due to positive eﬀects on glucose homeostasis,
atherogenic proteins, endothelial function, and inﬂamma-
tion, these compounds may also be of beneﬁt in other related
pathologies,suchasCVD[81].TherearecurrentlytwoTZDs
in clinical use, rosiglitazone and pioglitazone. The ﬁrst agent
in this class (troglitazone) was withdrawn after reports of
hepatic toxicity and failure. Clinical studies have shown that
TZDs improve insulin resistance and lower blood glucose
levels in subjects with Type 2 diabetes. Growing evidence
support the concept that rosiglitazone and pioglitazone have
beneﬁcial eﬀects on several cardiovascular risk factors and
surrogate markers, beyond their eﬀects on glycemic control
and the clinical signiﬁcance of the beneﬁcial eﬀects of TZDs
on CVD has been clariﬁed [82].
Two studies demonstrated that treatment with piogli-
tazone inhibit the progression of carotid intima/medial
thickness (IMT) and coronary atheroma volume, which is
important surrogates of atherosclerosis [83, 84]. PROspec-
tive pioglitAzone Clinical Trial In macroVascular Events
(PROactive) trial, which was a secondary prevention trial
in patients with type 2 diabetes and preexisting CVDs
(previous MI, stroke or peripheral vascular disease), was
the ﬁrst cardiovascular outcome study with a TZD to be
published [85]. It was a randomized double-blind trial
comparing the eﬃcacy of pioglitazone in reducing the
incidenceofnewmacrovasculareventsordeathwithplacebo
in 5238 patients with type 2 diabetes and macrovascular
disease. The primary endpoint was the composite of all-
cause mortality, nonfatal MI, stroke, ACS, endovascular or
surgical intervention in the coronary or leg arteries, and
amputation above the ankle. Pioglitazone treatment resulted
in a nonsigniﬁcant 10% reduction (HR 0.90; P = .095)
in the primary composite endpoint and a signiﬁcant 16%
reduction (HR 0.94; P = .027) in the main secondary
endpoint of all-cause mortality, nonfatal MI, and stroke
combined, in comparison with placebo, after a mean fol-
lowup of about 34.5 months. Although there was a 1.6%
absolute increase in heart failure hospitalizations in the
pioglitazone group compared with the placebo group, the
number of heart-failure-related deaths was almost identical.
In subgroup analysis (PROactive 05), pioglitazone treatment
resulted in a 28% reduction (HR 0.82; P = .04) of
fatal and nonfatal MI and a signiﬁcant 37% reduction
(HR 0.67; P = .035) of acute coronary syndrome in
patients who had experienced a previous MI six months
or more before randomization [86]. Moreover, in patients
who had experienced a previous stroke six months or
more before randomization, there was a signiﬁcant 47%
reduction (HR 0.53; P = .0085) of fatal or nonfatal
stroke and a marginally signiﬁcant 28% reduction (HR 72;
P = .0467) of the composite end point of cardiovascular
death, nonfatal MI, or nonfatal stroke (PROactive 04) [87].
In meta-analysis, pioglitazone has been reported not to
associate with increased risk of either MI or CV mortality
[88, 89].
Meanwhile, it has been reported that rosiglitazone treat-
ment is associated with overall increased incidence of MI
(OR 1.43; P = .03) and a potential increase of borderline
signiﬁcance in the risk of death from total CV causes (OR
1.64; P = .06) by meta-analysis [90]. Several analyses have
been performed that challenged these ﬁndings, but the CVD
risk of rosiglitazone is uncertain [91–93]. Another meta-
analyses of RCTs of rosiglitazone in patients with type 2
diabetes showed that rosiglitazone signiﬁcantly increased
the risk of MI (RR 1.42; P = .02) and heart failure
(RR 2.09; P<. 001), but not the risk of cardiovascular
mortality (RR 0.90; P = .53) [94]. Conversely, a pooled
analysis of 3 large rosiglitazone trials designed to speciﬁcally
test CV outcomes (a diabetes outcome progression trial,
rosiglitazone evaluated for cardiac outcomes and regulation
of glycemia in diabetes, and diabetes reduction assessmentPPAR Research 7
with ramipril and rosiglitazone medication) did not reach
statistical signiﬁcance for either MI (OR 1.29; P = .12)
or death due to CV causes (OR 0.90; P = .67) [95].
Furthermore, a meta-analysis of 86 trials did not ﬁnd a
statistically signiﬁcant increase in the overall rate of MI in
patients on rosiglitazone [96]. A further study is needed to
establish the utility of rosiglitazone in CVD.
There are some diﬀerences in the actions of piogli-
tazone and rosiglitazone. Diﬀerences in side chains are
responsible for diﬀerences between the compounds in
pharmacodynamic and pharmacokinetic properties, as well
as the side-eﬀect proﬁles. Pioglitazone has more beneﬁcial
eﬀects on the lipid proﬁle than rosiglitazone [97]. As men-
tioned earlier, rosiglitazone, but not pioglitazone, induced
c a r d i a ch y p e r t r o p h yb yan o n - P P A R γ-mediated pathway
[75]. Pioglitazone represses NF-κB activation and VCAM-1
expressioninaPPARα-dependentmanner[98].Pioglitazone
was recently reported to increase the number and function
of endothelial progenitor cells (EPCs) in patients with stable
coronary artery disease and normal glucose tolerance [99].
Pioglitazone may induce angiogenesis by modulating EPCs
mobilization and function. In the future, more mechanistic
studies are required to investigate the diﬀerences in action
between pioglitazone and rosiglitazone.
TZDs do not directly aﬀect left ventricular systolic
or diastolic function and may even be beneﬁcial [100].
However, data from the recently published meta-analyses
indicate that treatment with TZDs signiﬁcantly increase the
riskofCHF(RR1.72;P = .002)[101].Bothpioglitazoneand
rosiglitazone unambiguously increase risk of CHF, poten-
tially reﬂecting an inherent proclivity to induce edema [102].
Pioglitazone and rosiglitazone appeared to raise the risk of
CHF by similar amounts, but neither raised the incidence of
heart-failure-associated death [101]. Clinical studies report
TZD-induced peripheral ﬂuid retention, and an increase in
plasma volume in 2–5% of patients on monotherapy [103].
The exact mechanisms for TZD-induced ﬂuid retention
are not well understood, and it remains unclear whether
TZDs directly cause the development of de novo CHF. Fluid
retention was more likely to occur with concomitant insulin
use, and in patients with underlying cardiac dysfunction
or renal insuﬃciency. The level of vascular endothelial
growth factor is increased in the patients who develop
ﬂuid retention with TZD therapy and this may lead to
peripheral edema through increased vascular permeability
[104]. The insulin-sensitizing action of TZDs also induces
water and salt retention. PPARγ is highly expressed in the
kidney and collecting-duct-speciﬁc PPARγ knockout mice
demonstrated no eﬀects of TZD on ﬂuid retention or the
expressionlevelofsodiumchannelENaC-γ [105,106].These
ﬁndings suggest that activation of the sodium channel in the
collecting duct cells expressing PPARγ may be a mechanism
of ﬂuid retention. In patients without evidence of heart
failure, careful examination did not reveal any worsening of
left ventricular function by TZDs [107]. Of note, diabetes
itself aﬀects both diastolic and systolic functions and is an
independent risk factor for the development of CHF [108].
The American Heart Association (AHA) and American Dia-
betesAssociation(ADA)havereleasedaconsensusstatement
that advises caution regarding the use of TZDs in patients
with known or suspected heart failure [108]. Because there is
a possibility that TZDs may unmask asymptomatic cardiac
dysfunction by increasing plasma volume, they should be
avoided in patients with CHF of New York Heart Association
(NYHA) class III or IV.
Angiotensin II receptor blockers (ARBs) are widely used
for the treatment of hypertension, ischemic heart disease,
andheartfailure.ARBshavebeenreportedtohaveprotective
eﬀects on the cardiovascular system beyond blood pressure
lowering eﬀect in many clinical trials [109]. Telmisartan,
one of the ARBs, has recently been identiﬁed as a partial
activator of PPARγ. There is evidence that, in contrast to
some other ARBs, telmisartan may exert beneﬁcial eﬀects
on insulin sensitivity through activation of PPAR-γ [110].
There is a structural resemblance between telmisartan and
PPAR-γ ligand pioglitazone, which suggests that telmis-
artan may activate the receptor. In vitro studies showed
that telmisartan acted as a partial agonist of PPAR-γ and
modulated the expression of PPAR-γ target genes involved
in carbohydrate and lipid metabolism [111]. Telmisartan
induces adiponectin expression via PPARγ activation [112],
and adiponectin has been reported to induce angiogenesis
[113]. Telmisartan-induced proliferation of human EPCs via
PPARγ-dependent PI3K/Akt signaling pathway [114]. Since
telmisartan has both eﬀects of angiotensin II blockade and
PPARγ activation as well as getting out from under the
condition of vascular dysfunction, it might be expected to
recover vascular function and promote neoangiogenesis in
the ischemic tissue via proliferation of EPCs beyond the
class eﬀects of ARBs in the clinical setting. In the Ongoing
TelmisartanAloneandinCombinationwithRamiprilGlobal
Endpoint Trial (ONTARGET), telmisartan was reported to
beaseﬀective as ramipril forthe primary cardiovascularout-
come during a 56-month followup but was better tolerated
[115]. The utility of telmisartan by having the additional
value of PPARγ activity is expected.
7. Conclusions
Since the discovery of nuclear PPARγ in the early 1990s, it
becomes evident that PPARγ play an important role in the
cardiovascular system and implicate in several CVDs. The
data from in vitro studies suggest that TZDs exert direct
actions on vascular cells and cardiomyocytes, independent
of their glucose-mediated mechanisms. The subsequent
development of PPARγ agonists and gene-modiﬁed ani-
mals has highlighted the involvement of these receptors in
numerous biological pathways. However, the complexity of
PPARγ activation, in combination with their diverse tissue
distribution and lack of speciﬁcity of currently available
PPARγ agonists makes therapeutic modiﬁcation of PPARγ
pathways a challenging goal. A detailed understanding of the
role of PPARγ in the cardiovascular system is required in
order to delineate the precise mechanisms by which PPARγ
maymodifycellularCVDprocessesandenableidentiﬁcation
of eﬀective therapeutic targets. Further studies using tissue-
speciﬁc gene targeting mice are necessary to address the
pleiotropic eﬀects of PPARγ on the cardiovascular system.8 PPAR Research
Future research aimed at the development of more eﬀective
agonists. Dual PPARα/γ,P P A R δ/γ agonist, pan PPARα/δ/γ
agonists, and combination of PPARγ with other cardio-
vascular drugs will address some of the issues currently
surrounding the potential use of PPARγ activators in the
treatment of CVD.
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